End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.1 CNY | -3.95% | -1.54% | -40.78% |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- With a P/E ratio at 14.31 for the current year and 7.57 for next year, earnings multiples are highly attractive compared with competitors.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.72 for the current period. Therefore, the company is undervalued.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.78% | 1.21B | C+ | ||
-19.14% | 8.22B | B+ | ||
+45.10% | 3.73B | C+ | ||
-7.18% | 2.46B | - | ||
-38.71% | 2.46B | B- | ||
-8.66% | 2.36B | B- | ||
-13.72% | 1.78B | C- | ||
-19.73% | 1.52B | A- | ||
+8.32% | 1.12B | B+ | ||
-12.27% | 1.09B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300244 Stock
- Ratings Dian Diagnostics Group Co.,Ltd.